Pharmafile Logo

Genesis Research Group announces inaugural membership of ISPOR Corporate Partnership Program

Genesis Research Group, a pioneer of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, today announces it has joined selected organizations as an inaugural member of ISPOR—The Professional Society for Health Economics and Outcomes Research’s Corporate Partnership Program. This strategic alliance with ISPOR reinforces Genesis Research Group’s commitment to advancing HEOR to inform healthcare decision-making and improve patient access to life-changing therapies.

ISPOR partner seal

As a member of ISPOR’s Corporate Partnership Program, Genesis Research Group will collaborate with ISPOR and the global HEOR community to support initiatives that advance and strengthen HEOR, in alignment with ISPOR’s Strategic Plan 2030. This includes cutting edge research, education and training, and enhancing health outcomes research through evidence-based practices throughout the wider healthcare industry.

“We are very excited to launch the new Corporate Partner Program, welcome Genesis Research Group, and invite them and other organizations to contribute to ISPOR’s vision of a world where healthcare is accessible, effective, efficient, and affordable for all,” commented Rob Abbott, CEO of ISPOR. “Organizations who become ISPOR Corporate Partners will take an active role in the Society’s mission to improve healthcare decisions and achieving this vision, while elevating their presence with key stakeholders.”

“The importance of leveraging HEOR to inform healthcare decision-making has never been greater. By supporting ISPOR and becoming an inaugural member of its Corporate Partnership Program, we are reaffirming our dedication to leveraging real-world evidence, market access, and HEOR transparently and ethically to ensure that healthcare decisions are guided by high-quality evidence,” said David W. Miller, CEO of Genesis Research Group. “We are delighted to join other industry leaders in taking an active role in shaping the future of HEOR.”

MEET GENESIS RESEARCH GROUP AT ISPOR 2025 IN MONTREAL!

Contact solutions@genesisrg.com.

This content was provided by Genesis Research Group

Company Details

 Latest Content from  Genesis Research Group 

ISPOR’s 2026–2027 HEOR Trends report: The Era of Evidence Judgment

In response to ISPOR’s recently published 2026-2027 HEOR Trends, David Miller, CEO, Genesis Research Group, suggests that we’re no longer being evaluated on our ability to produce data, but on...

Tim Wright Updates ISPOR Europe MFN Pricing Presentation in New Interview

At ISPOR Europe in Glasgow, there were literal queues around the block for Tim Wright's HEOR Theater presentation 'MFN Pricing: More Fun to Navigate – A European Roadmap to Success,' with potentially...

Genesis Research Group contributes strong scientific program to ISPOR Europe and warmly invites visitors to booth 212

Genesis Research Group is proud to be attending ISPOR Europe 2025 in Glasgow from 10-12th November with a strong scientific program that includes an HEOR Theater session, contributions to 10...

ISPOR hosts expert webinar exploring the value of ECAs for regulatory and HTA evidence needs

On Tuesday, October 7th, you are invited to join a Genesis Research Group-led webinar exploring the value of External Control Arm (ECA) studies. Gaining traction as part of evidence generation...

Dave W. Miller interviewed by Paige McGarry on the unique challenges faced by biotech companies

HealthEconomics.com interviews David W. Miller, CEO of Genesis Research Group, to discuss the unique challenges faced by biotech companies in evidence generation, market access, and stakeholder engagement.

Genesis Research Group Appoints Tim Wright as Executive Vice President, Access and Pricing

Genesis Research Group, a leading provider of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, announces the appointment of Tim Wright as Executive Vice...

Navigating US market access analytics: A conversation with Ki Park

In the rapidly evolving landscape of healthcare and pharmaceutical market access, data analytics has become a critical component for making informed decisions. We sat down with Ki Park, our Vice...

Strategy. Insights. Access. Genesis Research Group outlines its integrated, data-driven solutions for US and global access and pricing.

In today’s rapidly evolving environment, US and global access and pricing decisions demand robust evidence, rigorous analysis, and strategic precision. Following Genesis Research Group's recent expansion of its real-world data...

Genesis Research Group announces inaugural membership of ISPOR Corporate Partnership Program

Genesis Research Group, a pioneer of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, today announces it has joined selected organizations as an inaugural...

Genesis Research Group survey discovers how payers are responding to Maximum Fair Prices (MFPs) under the Inflation Reduction Act

To better understand how MFPs might impact payer utilization management strategies, rebate negotiations, and business approaches, Genesis Research Group employed their RPR stakeholder engagement platform and vetted stakeholder network to...